Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes
Treatment goals defined by the absolute Psoriasis Area and Severity Index (PASI) scores offer certain advantages in the clinical setting. In order to investigate potential treatment targets, this study evaluated absolute PASI outcomes relative to other measures of response using data from two random...
Saved in:
Main Authors: | Luís Puig (Author), Martin Dossenbach (Author), Lovisa Berggren (Author), Anders Ljungberg (Author), Claus Zachariae (Author) |
---|---|
Format: | Book |
Published: |
Medical Journals Sweden,
2019-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of Ixekizumab Treatment on Itch and Psoriasis Area and Severity Index in Patients with Moderate-to-Severe Plaque Psoriasis: An Integrated Analysis of Two Phase III Randomized Studies
by: Gil Yosipovitch, et al.
Published: (2018) -
Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials
by: Craig Leonardi, et al.
Published: (2020) -
An Analysis of Patient-reported Outcomes in IXORA-S: Comparing Ixekizumab and Ustekinumab over 52 Weeks in Moderate-to-severe Psoriasis
by: Lluís Puig, et al.
Published: (2020) -
The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain
by: Paulina Maravilla-Herrera, et al.
Published: (2023) -
PASI (Psoriasis Area and Severity Index) in the evaluation of the clinical manifestations of psoriasis
by: A. A. Kubanov, et al.
Published: (2017)